No Data
Nanjing Pharmaceutical: Full text of Nanjing Pharmaceutical\'s report for the first quarter of 2025
Full text of Nanjing Pharmaceutical\'s report for the first quarter of 2025
Nanjing Pharmaceutical (600713.SH): Has repurchased a total of 1.11% of the company's shares.
On April 25, Gelonghui reported that Nanjing Pharmaceutical (600713.SH) announced that as of April 24, 2025, the company has cumulatively repurchased 14.585301 million shares through centralized bidding, accounting for 1.11% of the company's total share capital, an increase of 0.99% compared to the last disclosed number. The highest transaction price for the buyback was 5.08 yuan/share, the lowest price was 4.69 yuan/share, and the total amount of funds paid was 71.598 million yuan (excluding transaction costs).
Nanjing Pharmaceutical (600713.SH): The 2025 restricted stock incentive plan has been approved by the Nanjing Municipal State-owned Assets Supervision and Administration Commission.
On April 10, Gelonghui reported that Nanjing Pharmaceutical (600713.SH) announced that it recently received the "Reply on the Implementation of the Restricted Stock Incentive Plan of Nanjing Pharmaceutical Co., Ltd." from the State-owned Assets Supervision and Administration Commission of Nanjing Municipal People's Government (hereinafter referred to as "Nanjing State-owned Assets Supervision and Administration Commission") (Ning Guo Zi Wei Kao [2025] No. 29). The Nanjing State-owned Assets Supervision and Administration Commission has agreed in principle to the "Draft of the Restricted Stock Incentive Plan of Nanjing Pharmaceutical Co., Ltd. for 2025" and requests submission to the shareholders' meeting for discussion in accordance with relevant regulations.
Nanjing Pharmaceutical: Full text of Nanjing Pharmaceutical\'s 2024 Annual Report
Nanjing Pharmaceutical: Summary of Nanjing Pharmaceutical\'s 2024 Annual Report
What NanJing Pharmaceutical Company Limited's (SHSE:600713) ROE Can Tell Us
